转化医学杂志2023，Vol.12Issue(6)：319-324,6.DOI:10.3969/j.issn.2095-3097.2023.06.005
AKT激活与非小细胞肺腺癌吉非替尼耐药性的关系探究
Relationship between AKT Activation and Gefitinib Resistance in Non-small Cell Lung Adenocarcinoma
摘要
Abstract
Objective To investigate the correlation between serine-threonine protein kinase B(AKT)activation and Gefitinib resistance in non-small cell lung adenocarcinoma.Methods A total of 100 patients with non-small cell lung adeno-carcinoma treated with Gefitinib from May 2020 to May 2022 were selected as the research subjects.According to whether Ge-fitinib resistance occurred,they were divided into drug resistance group(n =42)and non-drug resistance group(n =58).The expression of AKT protein in two groups of cancer tissues was compared.Multivariate Logistic regression analysis was used to investigate the influencing factors of Gefitinib resistance.The expression of AKT protein in patients with different clinico-pathological characteristics in drug resistance group was compared,and its correlation with clinicopathological characteristics was analyzed.The predictive efficacy of different influencing factors on Gefitinib resistance was evaluated by receiver operating characteristic(ROC)curve.Results The expression level of AKT protein in drug resistance group was higher than that in non-drug resistance group(P<0.05).Smoking history,clinical stage,lymph node metastasis and AKT expression level were independent risk factors for Gefitinib resistance in non-small cell lung adenocarcinoma patients(P<0.01).There were signif-icant differences in the expression level of AKT in patients with different clinical stages and lymph node metastasis(P<0.01).In the drug resistance group,AKT expression was positively correlated with clinical stage and lymph node metastasis(P<0.01).The area under the ROC curve(0.788)of AKT expression in predicting Gefitinib resistance in patients with non-small cell lung adenocarcinoma was larger than that of smoking history(0.697),clinical stage(0.654),and lymph node metastasis(0.640),respectively(P<0.05,P<0.01).Conclusion AKT is activated in patients with non-small cell lung adenocarcinoma resistant to Gefitinib,and is closely related to clinical stage and lymph node metastasis,which has a certain predictive value for Gefitinib resistance.关键词
癌,非小细胞肺/腺癌/吉非替尼/抗药性,肿瘤/丝氨酸-苏氨酸蛋白激酶B/淋巴结转移/危险因素/预测Key words
Carcinoma,non-small-cell lung/Adenocarcinoma/Gefitinib/Drug resistance,neoplasm/Serine-threonine protein kinase B/Lymph node metastasis/Risk factors/Prediction分类
医药卫生引用本文复制引用
杨慧,蒋文娟,谢伟彬,丁丹..AKT激活与非小细胞肺腺癌吉非替尼耐药性的关系探究[J].转化医学杂志,2023,12(6):319-324,6.基金项目
湖南省自然科学基金项目(2023JJ30371) （2023JJ30371）
